JP2013060380A - Composition for improving brain function, having black vinegar-derived ingredient as active ingredient - Google Patents

Composition for improving brain function, having black vinegar-derived ingredient as active ingredient Download PDF

Info

Publication number
JP2013060380A
JP2013060380A JP2011198950A JP2011198950A JP2013060380A JP 2013060380 A JP2013060380 A JP 2013060380A JP 2011198950 A JP2011198950 A JP 2011198950A JP 2011198950 A JP2011198950 A JP 2011198950A JP 2013060380 A JP2013060380 A JP 2013060380A
Authority
JP
Japan
Prior art keywords
black vinegar
brain function
composition
group
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011198950A
Other languages
Japanese (ja)
Inventor
Hiroaki Kanouchi
宏明 叶内
Masahiro Suzuki
雅大 鈴木
Masanobu Nagano
正信 長野
Tomoko Ueno
知子 上野
Kazunori Hashiguchi
和典 橋口
Naoto Hishida
直人 菱田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAKAMOTO JOZO KK
Kagoshima University NUC
Original Assignee
SAKAMOTO JOZO KK
Kagoshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAKAMOTO JOZO KK, Kagoshima University NUC filed Critical SAKAMOTO JOZO KK
Priority to JP2011198950A priority Critical patent/JP2013060380A/en
Publication of JP2013060380A publication Critical patent/JP2013060380A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To ascertain whether or not an ingredient derived from black vinegar has a brain function improving action, and to provide a composition for improving a brain function, having the black vinegar-derived ingredient as an active ingredient.SOLUTION: The invention provides the composition for improving a brain function, having the black vinegar-derived ingredient as an active ingredient. More specifically, the composition for improving a brain function having an ingredient specific to black vinegar which eliminates acetic acid from the black vinegar or unrefined black vinegar powder is provided.

Description

本発明は、黒酢由来成分を有効成分とする脳機能改善用組成物に関する。さらに詳しくは、黒酢から酢酸を除去した黒酢特有の成分または黒酢もろみ末を有効成分とする脳機能改善用組成物に関する。   The present invention relates to a composition for improving brain function comprising a black vinegar-derived component as an active ingredient. More specifically, the present invention relates to a composition for improving brain function comprising a black vinegar-specific component obtained by removing acetic acid from black vinegar or black vinegar moromi powder as an active ingredient.

2010年における認知症発症者の推計は、200万人とも言われている。iPS細胞の研究が進み、再生医療による治療方法が期待されているが、ガン化などのリスクがあるため、ヒトへの臨床応用の道筋は不透明である。そのため、認知症発症の一次予防、もしくは発症後もその進行を緩やかにする二次予防が重要である。
ここで、認知症を発症した脳では正常な脳に比べて高い酸化状態にあることが指摘されている。ブドウ果皮に含まれるレスベラトロールは、抗酸化作用を有し、認知障害を改善することが報告されている(非特許文献1)。本報告ではレスベラトロールの認知機能改善作用は抗酸化作用だけではなく、インスリン様増殖因子-1(IGF-1)の発現誘導を介した認知機能改善作用であると示唆されている。
一方、黒酢も高い抗酸化作用を有することが知られている。黒酢は、鹿児島県の福山町を発祥の地とし、JAS法により規定される米黒酢であり、陶器の壺に、蒸し米、麹、水を入れ、糖化、アルコール発酵、酢酸発酵までが1つの壺で進行し、さらに熟成させることで得られる独特の深い味わいを有する酢である。また、黒酢の発酵過程では副産物として黒酢もろみ末が産生されるが、この黒酢もろみ末は、水不溶性物質であり、食物繊維、β―グルカンおよびペプチドを含有しており、近年は健康素材としても注目されている。
黒酢は、昔はもっぱら調味料として用いられていたが、近年は黒酢の血圧を下げる効果や血液をサラサラにする効果が明らかとなり、さらに、脂質代謝改善作用、血糖低下作用などのエビデンスが得られ、実際に様々な生体機能調節機能を持つことが明らかにされつつある。しかし、黒酢または黒酢もろみ末等の黒酢由来成分が脳機能を改善するかどうかについてはこれまでに全く報告がない。
ここで黒酢の主成分である酢酸由来の物質については、一定の脳機能改善作用を有するという技術がある(例えば特許文献1)。本文献には、酢酸由来のN−アシルスフィンガニン等を有効成分とする脳機能改善用組成物について記載されている。
以上のとおり、酢酸由来の成分についての報告はあるものの、酢酸以外の黒酢の特有成分または黒酢もろみ末の脳機能改善作用については全く不明であった。
The estimated number of people with dementia in 2010 is said to be 2 million. Although research on iPS cells has progressed and therapeutic methods using regenerative medicine are expected, the path to clinical application to humans is unclear because of the risk of canceration. Therefore, primary prevention of dementia onset or secondary prevention that slows its progression after onset is important.
Here, it has been pointed out that the brain that has developed dementia is in a higher oxidation state than the normal brain. Resveratrol contained in grape skin has been reported to have an antioxidant effect and improve cognitive impairment (Non-patent Document 1). This report suggests that resveratrol's cognitive function-improving action is not only an anti-oxidative action, but also a cognitive function-improving action through induction of insulin-like growth factor-1 (IGF-1) expression.
On the other hand, black vinegar is also known to have a high antioxidant effect. Black vinegar is a rice black vinegar that originated in Fukuyama Town, Kagoshima Prefecture, and is regulated by the JAS Law. Put steamed rice, rice bran, and water in a potter's pot, until saccharification, alcoholic fermentation, and acetic acid fermentation. It is a vinegar with a unique deep taste that is obtained by proceeding with one jar and further aging. In addition, black vinegar mash powder is produced as a by-product during the fermentation process of black vinegar. This black vinegar mash powder is a water-insoluble substance and contains dietary fiber, β-glucan and peptides. It is also attracting attention as a material.
Black vinegar has been used exclusively as a seasoning in the past, but in recent years it has become clear that black vinegar has the effect of lowering blood pressure and smoothing blood, and there is evidence such as lipid metabolism improving action and blood sugar lowering action. It has been clarified that it has various biological function regulation functions. However, there has been no report so far on whether black vinegar or black vinegar-derived components such as black vinegar improves the brain function.
Here, there is a technology that a substance derived from acetic acid, which is the main component of black vinegar, has a certain brain function improving action (for example, Patent Document 1). This document describes a composition for improving brain function containing N-acyl sphinganine derived from acetic acid as an active ingredient.
As described above, although there are reports on components derived from acetic acid, the specific components of black vinegar other than acetic acid or the brain function-improving action of black vinegar mash is completely unknown.

特開2007−70342号公報JP 2007-70342 A

Harada N, Zhao J, Kurihara H, Nakagata N, Okajima K. Resveratrol im proves cognitive function in mice by increasing production of insulin-like growth fa ctor-I in the hippocampus. J Nutr Biochem. 2011 in press.Harada N, Zhao J, Kurihara H, Nakagata N, Okajima K. Resveratrol im proves cognitive function in mice by increasing production of insulin-like growth fa ctor-I in the hippocampus.J Nutr Biochem. 2011 in press.

本発明は、食品としての安全性が確認されている黒酢由来成分であって黒酢特有の成分を有効成分とする脳機能改善用組成物の提供を課題とする。   An object of the present invention is to provide a composition for improving brain function, which is an ingredient derived from black vinegar, which has been confirmed to be safe as food, and contains an ingredient specific to black vinegar as an active ingredient.

本発明者らは、黒酢由来成分に脳機能の改善作用があるか否かについて老化促進マウス(SAM P8)を用い、水迷路試験で評価したところ、驚くべきことに黒酢から酢酸を除した成分および黒酢もろみ末に認知機能の低下抑制作用を有することを初めて見出し、本発明を完成するに至った。
すなわち、本発明は以下の構成を有する。
(1)黒酢由来成分を有効成分とする脳機能改善用組成物。
(2)黒酢由成分が、黒酢から酢酸を除いた成分または黒酢もろみ末である前記(1)に記載の脳機能改善用組成物。
(3)脳機能改善がアルツハイマー症の改善である前記(1)または(2)に記載の脳機能改善用組成物。
(4)前記(1)から(3)のいずれかに記載の脳機能改善用組成物を含有する飲食品(ただし、黒酢および黒酢もろみ末を除く)。
The inventors of the present invention evaluated whether a component derived from black vinegar has an effect of improving brain function by using an aging accelerated mouse (SAM P8) in a water maze test. Surprisingly, acetic acid was removed from black vinegar. It was found for the first time that the ingredients and black vinegar moromi powder have a cognitive function lowering inhibitory effect, and the present invention has been completed.
That is, the present invention has the following configuration.
(1) A composition for improving brain function comprising a black vinegar-derived component as an active ingredient.
(2) The composition for improving brain function according to (1), wherein the black vinegar-based component is a component obtained by removing acetic acid from black vinegar or black vinegar mash.
(3) The composition for improving brain function according to (1) or (2), wherein the improvement of brain function is improvement of Alzheimer's disease.
(4) A food or drink containing the composition for improving brain function according to any one of (1) to (3) (excluding black vinegar and black vinegar mash).

本発明の黒酢由来成分を有効成分とする脳機能改善用組成物により、認知症の発症を予防し、また、発症後の進行を遅らせることができる。   With the composition for improving brain function comprising the black vinegar-derived component of the present invention as an active ingredient, the onset of dementia can be prevented and the progression after the onset can be delayed.

実施例1の動物実験スケジュールを示す図である。2 is a diagram showing an animal experiment schedule in Example 1. FIG. 実施例1および2のモリス水迷路試験に用いるプールの模式図を示す図である。プールは部屋の角に設置した。外部が視野に入らないように二面、実験者の後方に衝立てを立てた。プラットホームは透明のアクリル樹脂で出来ており、水面下に投入すると水面上から認知できない。左は上方からの図、右は側面から図。左図で示す点線は領域をわかりやすくするために示しており、実際にはプール底面に印はない。It is a figure which shows the schematic diagram of the pool used for the Morris water maze test of Example 1 and 2. FIG. The pool was set up at the corner of the room. Two screens were set up behind the experimenter to prevent the outside from entering the field of view. The platform is made of transparent acrylic resin and cannot be recognized from the surface of the water when thrown under the surface of the water. The figure on the left is from above and the figure on the right is from the side. The dotted line shown in the left figure is shown for easy understanding of the area, and there is actually no mark on the bottom of the pool. 実施例2の動物実験スケジュールを示す図である。FIG. 3 is a diagram showing an animal experiment schedule of Example 2. プローブテスト結果を示す図である(実施例1)。左図は、各摂食群の滞在時間を示し、右図は、通過回数を示す。(平均値+SD(n=5)。異なる文字間に有意差が有ることを示す(p<0.05))It is a figure which shows a probe test result (Example 1). The left figure shows the staying time of each feeding group, and the right figure shows the number of passages. (Average value + SD (n = 5), indicating that there is a significant difference between different characters (p <0.05)) 水迷路訓練期間(15日間)における、マウスを水面に放してからゴールとなるプラットホームまでの退避時間測定結果を示す図である(実施例2)。(R1のみn=16、その他n=9。各日の群間において異なる文字は有意差有り(p<0.05)。)(Example 2) which is a figure which shows the evacuation time measurement result to the platform used as a goal after releasing a mouse | mouth on the water surface in a water maze training period (15 days). (R1 only n = 16, other n = 9. Characters that differ between groups on each day are significantly different (p <0.05).) プローブテスト結果を示す図である(実施例2)。左図は、各摂食群の滞在時間を示し、右図は、通過回数を示す。(平均値+SD(n=5)。異なる文字間に有意差が有ることを示す。滞在時間:p<0.01、通過回数:P8-もろみ間p<0.05;P8-R1間、P8‐黒酢間p<0.01)It is a figure which shows a probe test result (Example 2). The left figure shows the staying time of each feeding group, and the right figure shows the number of passages. (Average value + SD (n = 5). Shows that there is a significant difference between different characters. Residence time: p <0.01, Number of passes: P8-Moromi p <0.05; P8-R1, P8-Black vinegar P <0.01)

本発明で用いられる黒酢とは、先に述べたように、JAS法により規定される米黒酢であり、本発明ではこのように定義される黒酢であればどのようなものでも用いることができ、好ましくは陶器の壺に蒸し米、麹、水を入れ、糖化、アルコール発酵、酢酸発酵までが1つの壺で進行し、さらに熟成させることで得られる独特の深い味わいを有する酢である。
本発明に用いられる黒酢もろみ末とは、壺を用いて黒酢をつくる際に生じる副産物である。水溶性画分は黒酢となり、不水溶性画分は圧搾、乾燥、粉末化され、黒酢もろみ末となる。その成分として食物繊維、β―グルカンおよびペプチドを含有している。
本発明の黒酢由来成分としては、黒酢を由来とし、本発明の作用効果を奏するものであればいずれでもよく、黒酢そのもののほかに、黒酢から酢酸成分を除いた成分、黒酢もろみ末が挙げられる。
なお、後述する試験において、黒酢から酢酸を除した成分について各試験を行ったのは、黒酢の主成分である酢酸成分による作用との違いを明確にするべく行ったものであり、その結果、黒酢から酢酸を除いた成分、および黒酢もろみ末に脳機能改善作用があることが判明したことから、脳機能改善作用は、黒酢を由来とする成分のうちでも酢酸以外の成分にあるといえる。
As described above, the black vinegar used in the present invention is rice black vinegar defined by the JAS method. In the present invention, any black vinegar as defined above may be used. It is a vinegar with a unique deep taste obtained by adding steamed rice, rice bran, water to a porcelain bowl, saccharification, alcoholic fermentation, and acetic acid fermentation in one bowl and further aging .
The black vinegar moromi powder used in the present invention is a by-product produced when black vinegar is made using koji. The water-soluble fraction becomes black vinegar, and the water-insoluble fraction is squeezed, dried and powdered, resulting in black vinegar mash. It contains dietary fiber, β-glucan and peptide as its components.
The black vinegar-derived component of the present invention may be any component as long as it is derived from black vinegar and exhibits the effects of the present invention. In addition to black vinegar itself, a component obtained by removing the acetic acid component from black vinegar, black vinegar Moromi powder is mentioned.
In addition, in the test to be described later, each test was performed on the component obtained by removing acetic acid from black vinegar in order to clarify the difference from the action by the acetic acid component that is the main component of black vinegar. As a result, it was found that the component obtained by removing acetic acid from black vinegar, and that mash mash of black vinegar has a brain function improving effect, so the brain function improving effect is a component other than acetic acid among the components derived from black vinegar. It can be said that.

本発明でいう脳機能改善作用とは、脳機能の低下を予防・抑制する作用をいい、認知症によるもののほか、加齢によるものも含む。   The brain function improving action referred to in the present invention means an action for preventing / suppressing a decrease in brain function, and includes those caused by aging in addition to those caused by dementia.

本発明の脳機能改善用組成物は、黒酢そのものでもよいし、黒酢から酢酸成分を除去した残りの成分そのものでもよいし、黒酢もろみ末そのもののほか、これらを本発明の作用に影響を与えない他の成分と混合したものであってもよい。
また、形態としては液体でもよいし、乾燥させた固体であってもよい。固体は、固形物であってもよいし、粉末状であってもよい。固体の場合は、適当な液体に溶解するかもしくは分散させ、または、適当な粉末担体と混合するかもしくはこれに吸着させ、場合によっては、さらにこれらに乳化剤、分散剤、懸濁剤、展着剤、浸透剤、湿潤剤、安定剤等を添加し、乳剤、油剤、水和剤、散剤、錠剤、カプセル剤、液剤等の製剤として使用することができる。製剤として使用する場合における、抽出物の使用量は製剤の形態によっても異なり、安全性に問題がないので特に上限は規定しない。
The composition for improving brain function of the present invention may be black vinegar itself, the remaining component itself obtained by removing the acetic acid component from black vinegar, or the black vinegar mash powder itself, which affects the action of the present invention. It may be a mixture with other components that do not give any.
Further, the form may be a liquid or a dried solid. The solid may be a solid or a powder. In the case of solids, it is dissolved or dispersed in a suitable liquid, or mixed with a suitable powder carrier or adsorbed thereto, and in some cases, further emulsifiers, dispersants, suspending agents, spreading Additives, penetrants, wetting agents, stabilizers and the like can be used as preparations such as emulsions, oils, wettable powders, powders, tablets, capsules, and liquids. When used as a preparation, the amount of the extract to be used varies depending on the form of the preparation, and there is no problem with safety, so there is no particular upper limit.

本発明の脳機能改善用組成物の投与対象はヒト、ヒト以外の動物が挙げられ、ヒト以外の動物としてはイヌ、ネコをはじめとするペット、ネズミ、ウサギなどの小動物、ゾウ、キリンなどの大型動物のいずれをも対象とすることができる。   Examples of the administration target of the composition for improving brain function of the present invention include humans and animals other than humans. Examples of animals other than humans include dogs, pets including cats, mice, small animals such as rabbits, elephants, and giraffes. Any large animal can be targeted.

本発明の脳機能改善用組成物を脳機能改善のためにヒトまたはヒト以外の動物に投与する方法は、経口投与が望ましく、製剤化したものでもよいし、飲食物・飼料として摂取することも可能である。
経口投与する場合の摂取量としては、脳機能改善効果がみられる量であればよく、たとえば、黒酢もろみ末としては、1日5〜100mg/kg体重、黒酢エキスとしては(黒酢10倍濃縮液として)8.3〜83mg/kg体重が好ましい。
The method for administering the composition for improving brain function of the present invention to humans or animals other than humans for improving brain function is preferably oral administration, and may be formulated, or may be ingested as food, drink or feed. Is possible.
For oral administration, the amount of ingestion may be any amount that can improve brain function. For example, as black vinegar moromi powder, 5 to 100 mg / kg body weight per day, 8.3-83 mg / kg body weight is preferred (as a double concentrate).

飲食物としては、チューインガム,キャンディ,錠菓,グミゼリー,チョコレート,ビスケットまたはスナック等の菓子、アイスクリーム,シャーベットまたは氷菓等の冷菓、飲料、プリン、ジャム、乳製品、調味料等が挙げられ、本発明組成物を添加したこれらの飲食物を日常的に摂取することで脳機能改善効果が得られる。飲食物における本発明組成物の含有量は当該飲食物の嗜好品としての味・風味等を損なわない範囲内で含まれていればよく、飲食品の種類および形態によってそれぞれ異なる。また、飼料としては通常与える飼料に混合して投与することができる。なお、本発明の黒酢は、薬物相互作用を調べた結果、薬物代謝に関連する遺伝子・タンパク質の発現に影響を及ぼさないことが判明したため、他の薬を併用した場合であっても副作用がなく、安全に摂取することが可能である。   Examples of foods and beverages include chewing gum, candy, tablet confectionery, gummy jelly, chocolate, biscuits or snacks, frozen confectionery such as ice cream, sherbet or ice confectionery, beverages, pudding, jam, dairy products, seasonings, etc. A brain function improving effect is obtained by daily intake of these foods and drinks to which the inventive composition is added. Content of this invention composition in food / beverage should just be contained in the range which does not impair the taste, flavor, etc. as a favorite product of the said food / beverage, and changes with kinds and forms of food / beverage products, respectively. Moreover, it can administer by mixing with the feed normally given as a feed. As a result of investigating the drug interaction, the black vinegar of the present invention was found to have no effect on the expression of genes and proteins related to drug metabolism, so there are side effects even when other drugs are used in combination. And can be taken safely.

〔試験例1〕飼料の製造
(1)黒酢および黒酢もろみ末の調製
(i)黒酢もろみ末
黒酢もろみ末は、壺造り米黒酢の発酵残渣(黒酢もろみ)をろ過圧搾機で圧搾し、搾り液と搾り粕に分離後、その搾り粕を真空乾燥機にて110℃、6.5時間乾燥させ、さらに148℃、0.2MPa、4〜5秒殺菌して得られた。
(ii)黒酢10倍濃縮液(黒酢エキス)
黒酢(坂元醸造株式会社製、坂元のくろず(製品名))1000mlを凍結乾燥し粉末化する。これに蒸留水を加え、再び凍結乾燥を行う。この作業を4回繰り返し、黒酢中の酢酸を完全に除去する。得られた粉末を蒸留水100mlに溶解したものを黒酢10倍濃縮液とする。
(2)飼料の調製
(i)CE2食
基本飼料として、日本クレア社製CREA Rodent Diet CE-2(日本クレアHP参照 http://www.clea-japan.com/Feed/ce2.html)をCE2食とした。飼料は、蒸気打ちによりペレット化した後、100℃で乾燥し、放射線滅菌(30kGy)したものを与えた。
以下、(ii)、(iii)においても同様の処理を行った。CE-2の栄養成分およびカロリー(飼料100g中の含有量)を以下に示す。

Moisture (%) 9.3
Crude protein (%) 25.1
Crude fat (%) 4.8
Crude fiber (%) 4.2
Crude ash (%) 6.7
NFE (%) 50.0
Energy (kcal) 343.1
硬度(kg/cm2) 27.1

(ii)黒酢エキス添加CE2食
基本飼料であるCE2食99.75%に黒酢10倍濃縮液を0.25%添加したものを黒酢エキス添加CE2食とした。
(iii)もろみ添加CE2食
基本飼料であるCE2食99.5%に黒酢もろみ末を0.5%添加したものをもろみ添加CE2食とした。
[Test Example 1] Production of feed (1) Preparation of black vinegar and black vinegar moromi powder (i) Black vinegar moromi powder Black vinegar moromi powder is a squeezing machine for fermented residue of black rice vinegar (black vinegar moromi) After squeezing with squeezed and separated into squeezed liquid and squeezed squeezed pear, the squeezed sachet was dried at 110 ° C. for 6.5 hours in a vacuum dryer and further sterilized at 148 ° C., 0.2 MPa for 4 to 5 seconds.
(Ii) Black vinegar 10 times concentrate (black vinegar extract)
1000 ml of black vinegar (Sakamoto Brewing Co., Ltd., Sakamoto Kurozu (product name)) is freeze-dried and powdered. Distilled water is added to this and freeze-dried again. This process is repeated 4 times to completely remove acetic acid from black vinegar. A solution obtained by dissolving the obtained powder in 100 ml of distilled water is used as a black vinegar 10-fold concentrated solution.
(2) Preparation of feed (i) CE2 meal As a basic feed, CREA Rodent Diet CE-2 manufactured by CLEA Japan (see CLEA Japan http://www.clea-japan.com/Feed/ce2.html) is CE2. It was food. The feed was pelletized by steaming, dried at 100 ° C., and sterilized by radiation (30 kGy).
Thereafter, the same processing was performed in (ii) and (iii). The nutritional components and calories of CE-2 (content in 100g of feed) are shown below.

Moisture (%) 9.3
Crude protein (%) 25.1
Crude fat (%) 4.8
Crude fiber (%) 4.2
Crude ash (%) 6.7
NFE (%) 50.0
Energy (kcal) 343.1
Hardness (kg / cm 2 ) 27.1

(Ii) Black vinegar extract-added CE2 meal A black vinegar extract-added CE2 meal was obtained by adding 0.25% of black vinegar 10-fold concentrated solution to the basic feed CE2 meal 99.75%.
(Iii) Moromi-added CE2 meal The mash-added CE2 meal was obtained by adding 0.5% black vinegar moromi powder to 99.5% of the CE2 meal as the basic feed.

〔実施例1〕SAM P8マウスの認知機能に対する米黒酢もろみ末の効果
1.試験方法
(1)動物飼育
5週齢雄の老化促進マウスSAM P8(10匹)およびSAMP8と同系統の老化抵抗マウスSAM R1(5匹)を日本SLCから購入した。一週間の予備飼育後に群分けを行なうための予備水迷路試験を5日間行った。泳ぎに異常が認められる個体が集中しないように2つの群(各群5匹)に分けた。1群(R1群)にはCE2食、2群(P8群)にはCE2食、3群(P8もろみ群)には0.5%(w/w)もろみ末添加CE2食を与えた。CE2食およびもろみ末添加CE2食の作製は日本クレア(株)に委託した。
摂食開始から14週間後(21週齢)、10日間の水迷路試験を開始し、11日目にプローブテストを行った。水迷路試験を行っている期間も各実験食を与えた。スケジュールを図1に示した。
マウスは24週齢時にエーテル麻酔下で心採血により全血を採取し安楽死させた。採血後、脳、肝臓、腎臓、肺、下行大動脈、睾丸、脾臓、心臓、腎臓周辺脂肪、睾丸周辺脂肪を摘出し重量を測定した後、液体窒素で凍結した。採取した血液から血漿を分離した。血漿中過酸化脂質(TBARS)測定(和光純薬)は採血量が充分であった各群3匹で行った。脳、肝臓および腎臓から組織ホモジネートを作製し、TBARS濃度および蛋白質濃度を測定した。動物の飼育は気温20℃、12時間光照射 (8:00-20:00、白熱蛍光灯) の環境下で行った。
なお、本実験は鹿児島大学動物実験委員会で承認された後(A10029号)、動物の愛護及び管理に関する法律(動物愛護法)(平成17年6月22日公布, 平成18年6月1日施行、環境省)を遵守して行った(実施例2においても同様)。
[Example 1] Effect of rice black vinegar moromi powder on cognitive function of SAM P8 mice Test method (1) Animal breeding
Five-week-old male aging-promoting mice SAM P8 (10 mice) and aging-resistant mice SAM R1 (5 mice) of the same strain as SAMP8 were purchased from Japan SLC. A preliminary water maze test was conducted for 5 days after grouping for one week. It was divided into two groups (5 each) so that individuals with abnormal swimming were not concentrated. Group 1 (R1 group) received CE2 meals, Group 2 (P8 group) received CE2 meals, and Group 3 (P8 moromi group) received 0.5% (w / w) moromi powder added CE2 meals. Production of CE2 meal and moromi powder added CE2 meal was entrusted to CLEA Japan.
14 weeks after the start of feeding (21 weeks of age), a 10-day water maze test was started, and a probe test was conducted on the 11th day. Each experimental meal was also given during the water maze test. The schedule is shown in FIG.
At 24 weeks of age, whole blood was collected by cardiac blood sampling under ether anesthesia and euthanized. After blood collection, the brain, liver, kidney, lung, descending aorta, testicle, spleen, heart, kidney peripheral fat and testicular fat were removed and weighed and then frozen in liquid nitrogen. Plasma was separated from the collected blood. Plasma lipid peroxide (TBARS) measurement (Wako Pure Chemical Industries) was performed by 3 animals in each group with sufficient blood collection. Tissue homogenates were prepared from brain, liver and kidney, and TBARS concentration and protein concentration were measured. Animals were raised in an environment with an air temperature of 20 ° C and 12 hours of light irradiation (8: 00-20: 00, incandescent fluorescent lamp).
This experiment was approved by the Animal Experiment Committee of Kagoshima University (A10029), then the Act on the Protection and Control of Animals (Animal Protection Act) (promulgated on June 22, 2005, June 1, 2006) (The same applies to Example 2).

(2)モリス水迷路試験
本試験に用いるプールの模式を図2に示す。円形のプールの直径は1.2mであり、部屋の角に設置し、衝立てを立ててプールの四方を覆った。ゴールとなる足場(プラットホーム)はプールを4分割した右上の領域に水面からは認知できないように沈めた。プラットホームの反対側の左下プール脇に目印となるダンボールを置き、実験者はプール右下に座った。水温は25℃に温めた。プラットホームを沈めていない領域にマウスを投入し、プラットホームにたどり着く時間を測定した。一日に左上、左下、右下からのゴールまでの到着時間を3回測定した。
本試験では、摂食開始から14週間後(21週齢)から水迷路試験を開始した。10日間を訓練期間とし、11日目にプローブテストを実施した。すなわち、プラットホームを撤去した条件でマウスを70秒間泳がせた場合にプラットホーム沈めていた場所を通過する回数およびそのエリアの滞在時間を数値化して認知能力を判定した。
(2) Morris water maze test A schematic of the pool used in this test is shown in FIG. The diameter of the circular pool was 1.2m, and it was installed at the corner of the room and covered the four sides of the pool with a screen. The goal platform was submerged in the upper right area, which was divided into 4 pools, so that it could not be recognized from the water surface. A cardboard as a landmark was placed beside the lower left pool on the opposite side of the platform, and the experimenter sat in the lower right of the pool. The water temperature was warmed to 25 ° C. Mice were placed in an area where the platform was not submerged, and the time to reach the platform was measured. The arrival time from the upper left, lower left, and lower right to the goal was measured three times a day.
In this study, the water maze test was started 14 weeks after the start of feeding (21 weeks of age). The training period was 10 days, and the probe test was conducted on the 11th day. That is, when the mouse was allowed to swim for 70 seconds under the condition where the platform was removed, the number of passes through the place where the platform was submerged and the staying time in the area were quantified to determine the cognitive ability.

(3)統計解析
統計解析はSPSSバージョン17ソフトウェアを利用した。多重比較はDunnett法で行なった。
(3) Statistical analysis SPSS version 17 software was used for statistical analysis. Multiple comparison was performed by Dunnett's method.

2.試験結果
(1)もろみ末摂取後の体重、組織重量
表1に実験開始時から屠殺時までの体重の変化を示した。R1群に比べP8群は体重増加量、摂食効率が低かった。P8もろみ群はP8群に比べて摂食量が増え、体重増加量および摂食効率がR1群と同程度であった。表2に屠殺時の体重1gあたりの臓器重量(mg)を示した。P8群は体重が軽いため各組織重量値が大きくなっている。
2. Test results (1) Body weight and tissue weight after ingestion of moromi powder Table 1 shows changes in body weight from the start of the experiment to the time of sacrifice. Compared to the R1 group, the P8 group had lower weight gain and feeding efficiency. The P8 Moromi group had more food intake than the P8 group, and the body weight gain and feeding efficiency were similar to those of the R1 group. Table 2 shows the organ weight (mg) per gram body weight at the time of sacrifice. Since the body weight is light in the P8 group, each tissue weight value is large.

(2)過酸化脂質濃度
血清および各組織中酸化状態の検討は脂質の過酸化によって生じるチオバルビツール酸と反応するマロンジアルデヒド(MDA)等を指標とした(表3)。血漿、肝臓および腎臓においてTBARS値に顕著な差は認められなかったが、脳ではP8もろみ群で高い傾向にあった。
(2) Lipid peroxide concentration In the examination of the oxidation state in serum and tissues, malondialdehyde (MDA) that reacts with thiobarbituric acid produced by lipid peroxidation was used as an index (Table 3). There was no significant difference in TBARS levels in plasma, liver and kidney, but the brain tended to be higher in the P8 mash group.

(3)水迷路試験
(3−1)10日間の訓練期間においては、各群間でゴールへの到達時間に差は認められなかった。
(3−2)プローブテスト
11日目に行ったプローブテストの結果を図4に示す。左図はプラットホームを設置していた領域に滞在した時間(滞在時間)、右図はプラットホームを設置していた上を通過した回数(通過回数)をグラフ化した。
P8もろみ群はR1群と同程度の滞在時間および通過回数であった。P8群に比べ、P8もろみ群では滞在時間および通過回数が有意に増加した。水泳スピードに各群間で顕著な差はなかった。
(3) Water maze test (3-1) During the training period of 10 days, there was no difference in the time to reach the goal between the groups.
(3-2) Probe test
The results of the probe test performed on the 11th day are shown in FIG. The graph on the left shows the time spent in the area where the platform was installed (stay time), and the diagram on the right shows the number of passes (number of passes) that passed over the platform.
The P8 moromi group had the same residence time and number of passages as the R1 group. Compared with the P8 group, the residence time and the number of passages increased significantly in the P8 Moromi group. There was no significant difference in swimming speed between groups.

〔実施例2〕老化促進マウス認知障害に対するもろみ末および黒酢エキスの効果
1.試験方法
(1)動物飼育
10週齢雄の老化促進マウスSAM P8(27匹)と同系統で老化抵抗マウスSAM R1(16匹)を日本SLCから購入した。一週間の予備飼育後に群分けを行なうための予備水迷路試験を5日間行った。泳ぎに異常が認められる個体が集中しないように三つの群に分けた。R1CE2群はSAM R1(n=16)にCE2食を、P8 CE2群はSAM P8(n=9)にCE2食を、P8もろみ群はSAM P8(n=9)に0.5% (w/w)もろみ添加CE2食を、P8 黒酢群はSAM P8(n=9)に0.25% (w/w)黒酢エキス添加CE2食を与えた。23日間自由摂食自由飲水後に水迷路試験を行った。15日間を訓練期間とし、16日目にプローブテストを実施した。水迷路試験を行っている期間も各実験食を与えた。スケジュールを図3に示した。
実験終了後、心採血により全血を採取し安楽死させた。採血後、脳、肝臓、腎臓、肺、睾丸、脾臓、心臓、腎臓周辺脂肪、睾丸周辺脂肪を摘出し重量を測定した後、液体窒素で凍結した。採取した血液から血漿と血清を分離した。血漿は過酸化脂質(TBARS)測定(和光純薬)に用いた。凍結脳組織ホモジネートを作製して組織中の過酸化脂質(TBARS)を測定した。動物の飼育は気温20℃、12時間光照射 (8:00~20:00、白熱蛍光灯) の環境下で行った。
[Example 2] Effect of moromi powder and black vinegar extract on cognitive impairment in aging-promoted mice Test method (1) Animal breeding
Ten-week-old male aging-promoting mice SAM P8 (27 mice) and aging-resistant mice SAM R1 (16 mice) were purchased from Japan SLC. A preliminary water maze test was conducted for 5 days after grouping for one week. It was divided into three groups so that individuals with abnormal swimming were not concentrated. R1CE2 group is SAM R1 (n = 16) with CE2 diet, P8 CE2 group is SAM P8 (n = 9) with CE2 diet, P8 Moromi group is SAM P8 (n = 9) with 0.5% (w / w) The moromi-added CE2 diet, the P8 black vinegar group gave SAM P8 (n = 9) a 0.25% (w / w) black vinegar extract-added CE2 diet. A water maze test was conducted after 23 days free drinking and drinking. The training period was 15 days, and the probe test was conducted on the 16th day. Each experimental meal was also given during the water maze test. The schedule is shown in FIG.
After the experiment was completed, whole blood was collected by cardiac blood sampling and euthanized. After blood collection, brain, liver, kidney, lung, testis, spleen, heart, kidney peripheral fat and testicular fat were removed and weighed and then frozen in liquid nitrogen. Plasma and serum were separated from the collected blood. Plasma was used for lipid peroxide (TBARS) measurement (Wako Pure Chemical Industries). A frozen brain tissue homogenate was prepared and lipid peroxide (TBARS) in the tissue was measured. Animals were raised in an environment with an air temperature of 20 ° C. and 12 hours of light irradiation (8: 00-20: 00, incandescent fluorescent light).

(3)モリス水迷路試験
訓練期間を15日間とした以外は実施例1と同様に行った。
(3) Morris water maze test The Morris water maze test was conducted in the same manner as in Example 1 except that the training period was 15 days.

(4)統計解析
実施例1と同様に行った。
(4) Statistical analysis It carried out similarly to Example 1.

2.試験結果
(1)体重、組織重量
表4に実験開始時と屠殺時の体重を示した11週齢のSAM R1マウスとSAM P8マウスの体重を比べるとSAM P8マウスの体重が有意に軽かった。屠殺時17wkの体重もまた11wkと同様に有意な差が認められたが、P8群、P8もろみ群、P8黒酢群の間に有意な差は認められなかった。体重増加量にも有意差は認められなかったがP8もろみ群は他の群と比べて高値であった。
表5に屠殺時の体重1gあたりの臓器重量(mg)を示した。R1マウスに比べてP8マウスの体重が軽いため各組織の体重あたりの臓器重量はR1マウスに対してP8マウスの各群で値が大きくなっている。しかし、睾丸周辺および腎臓周辺脂肪重量値はR1マウスに比べてP8マウスで小さい。
2. Test Results (1) Body Weight and Tissue Weight Table 11 shows that the body weight of the SAM P8 mice was significantly lighter than that of the 11-week-old SAM R1 mice and SAM P8 mice whose body weights were shown at the start of the experiment and at the time of sacrifice. The body weight of 17 wk at the time of slaughter was also significantly different from 11 wk, but no significant difference was found among the P8 group, the P8 moromi group, and the P8 black vinegar group. There was no significant difference in weight gain, but the P8 Moromi group was higher than the other groups.
Table 5 shows the organ weight (mg) per gram body weight at the time of sacrifice. Since the body weight of the P8 mouse is lighter than that of the R1 mouse, the organ weight per body weight of each tissue is larger in each group of the P8 mouse than the R1 mouse. However, the testicular and peripheral kidney fat weight values are smaller in P8 mice than in R1 mice.

(2)過酸化脂質濃度
実験終了時の血漿及び脳中過酸化脂質濃度を表6に示した。血漿では、R1マウスに比べてP8マウスで有意に高値を示し、P8マウスに対して、P8黒酢群およびもろみ群は有意な低値を示した。脳においては、R1マウスに比べてP8マウスで有意に高値を示し、P8マウスに対して、P8黒酢は有意な低値を示した。
(2) Lipid peroxide concentration Plasma and brain lipid peroxide concentrations at the end of the experiment are shown in Table 6. In plasma, the P8 mice showed significantly higher values than the R1 mice, while the P8 black vinegar group and the moromi group showed significantly lower values than the P8 mice. In the brain, P8 mice showed significantly higher values than R1 mice, and P8 black vinegar showed significantly lower values than P8 mice.

(3)水迷路試験
(3−1)15日間の訓練期間において、マウスを水面に放してからゴールとなるプラットホームまでの退避時間を測定した。各マウス3回の試験を行い、群内での平均値をグラフ化し、図5に示した。P8群に比べてP8もろみ群およびP8黒酢群はゴール到着時間が早い傾向があり、トレーニング開始12日以降に有意な差が認められる場合があった。P8群とR1群の間に有意な差は認められなかったが、R1群で早い傾向が認められた。
(3−2)プローブテスト
16日目に行ったプローブテストの結果を図6に示した。滞在時間は、P8マウスに対してP8黒酢群で有意に増加した。通過回数に関しては、P8マウスに対して、P8もろみ群、P8黒酢群いずれも有意に増加した。
(3) Water maze test (3-1) During a 15-day training period, the evacuation time from the release of the mouse to the surface of the water until reaching the goal platform was measured. Each mouse was tested 3 times, and the average value within the group was graphed and shown in FIG. Compared to the P8 group, the P8 Moromi group and the P8 black vinegar group tended to have a faster goal arrival time, and there were cases where a significant difference was observed after 12 days of training. There was no significant difference between the P8 group and the R1 group, but an early trend was observed in the R1 group.
(3-2) Probe test
The results of the probe test performed on the 16th day are shown in FIG. Residence time was significantly increased in the P8 black vinegar group compared to P8 mice. Regarding the number of passages, the P8 moromi group and the P8 black vinegar group significantly increased compared to the P8 mice.

〔考察〕
実施例1において、老化促進マウス(SAM P8)で認知機能の低下が認められたが、もろみ末添加食によって認知機能低下抑制効果が認められた。実施例2において、摂食期間を延長し、さらに週齢の高いマウスを用いて、もろみ末の効果の再現性および黒酢添加食の認知能力を検討したところ、もろみ末および黒酢ともに認知能力低下の抑制作用が認められた。以上より、壺造り米黒酢由来成分に脳機能改善作用があることが明らかとなった。
[Discussion]
In Example 1, a decrease in cognitive function was observed in the senescence-accelerated mouse (SAM P8). In Example 2, the feeding period was extended, and the reproducibility of the effect of moromi powder and the cognitive ability of the black vinegar-added food were examined using mice that were aged older. An inhibitory effect on the decrease was observed. From the above, it has been clarified that the ingredients derived from koji-making rice black vinegar have an effect of improving brain function.

認知症の発症は患者の生活の質をさげるだけではなく、介護する家族にとっても大きなストレスとなる。高齢で発症しやすい本症は今後さらなる高齢化社会を迎える日本やその他先進国でも大きな問題である。根本的な治療方法が無い現在において、本発明の黒酢由来成分を有効成分とする脳機能改善用組成物により認知症の発症を抑制し、また発症した認知症の進行を緩やかにすることができる。   The onset of dementia not only reduces the quality of life of the patient, but also creates great stress for the caring family. This disease, which is likely to occur at an older age, is a major problem in Japan and other developed countries, which will face an aging society in the future. At present, when there is no fundamental treatment method, the composition for improving brain function comprising the black vinegar-derived component of the present invention as an active ingredient can suppress the onset of dementia and slow the progression of the onset of dementia. it can.

Claims (4)

黒酢由来成分を有効成分とする脳機能改善用組成物。   A composition for improving brain function comprising a black vinegar-derived component as an active ingredient. 黒酢由来成分が、黒酢から酢酸成分を除いた成分または黒酢もろみ末である請求項1に記載の脳機能改善用組成物。   The composition for improving brain function according to claim 1, wherein the black vinegar-derived component is a component obtained by removing an acetic acid component from black vinegar or a black vinegar mash. 脳機能改善がアルツハイマー症の改善である請求項1または2に記載の脳機能改善用組成物。   The composition for improving brain function according to claim 1 or 2, wherein the improvement of brain function is improvement of Alzheimer's disease. 請求項1から3のいずれかに記載の脳機能改善用組成物を含有する飲食品(ただし、黒酢および黒酢もろみ末を除く)。
A food or drink containing the composition for improving brain function according to any one of claims 1 to 3 (except black vinegar and black vinegar mash).
JP2011198950A 2011-09-13 2011-09-13 Composition for improving brain function, having black vinegar-derived ingredient as active ingredient Pending JP2013060380A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011198950A JP2013060380A (en) 2011-09-13 2011-09-13 Composition for improving brain function, having black vinegar-derived ingredient as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011198950A JP2013060380A (en) 2011-09-13 2011-09-13 Composition for improving brain function, having black vinegar-derived ingredient as active ingredient

Publications (1)

Publication Number Publication Date
JP2013060380A true JP2013060380A (en) 2013-04-04

Family

ID=48185395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011198950A Pending JP2013060380A (en) 2011-09-13 2011-09-13 Composition for improving brain function, having black vinegar-derived ingredient as active ingredient

Country Status (1)

Country Link
JP (1) JP2013060380A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015137237A (en) * 2014-01-21 2015-07-30 国立大学法人北海道大学 non-alcoholic fatty liver inhibitor
JP2017052710A (en) * 2015-09-08 2017-03-16 国立大学法人愛媛大学 Degranulation inhibitor
EP3632421A4 (en) * 2017-05-30 2021-02-24 Morinaga Milk Industry Co., Ltd. Composition for improving brain function

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015137237A (en) * 2014-01-21 2015-07-30 国立大学法人北海道大学 non-alcoholic fatty liver inhibitor
JP2017052710A (en) * 2015-09-08 2017-03-16 国立大学法人愛媛大学 Degranulation inhibitor
EP3632421A4 (en) * 2017-05-30 2021-02-24 Morinaga Milk Industry Co., Ltd. Composition for improving brain function

Similar Documents

Publication Publication Date Title
KR101651907B1 (en) Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension
JPWO2006093267A1 (en) Fermentation composition having immunomodulatory action
CN1527717A (en) Remedies
CN1791419A (en) Remedy
JP7007663B2 (en) Kuro-moji extract
CN106138101B (en) A kind of preparation method of chicken embryo placenta extract
JP2013060380A (en) Composition for improving brain function, having black vinegar-derived ingredient as active ingredient
JP2011500016A (en) Infant infant formula containing green tea and lactic acid bacteria
Bhattacharjee et al. Role of dietary serotonin and melatonin in human nutrition
CN1809369A (en) Extract from plant of japanese parsley family and process for producing the same
JP5926616B2 (en) Aging inhibitor
JP2009263344A (en) Fat cell differentiation-promoting agent
KR102218992B1 (en) Composition for preventing, ameliorating or treating autism spectrum disorder comprising Agathobaculum sp. strain as effective component
KR101307051B1 (en) Nature seasoning using micro algae protein hydrolysate and the manufacturing method thereof
KR100756550B1 (en) Composition containing pterocarpus santalinus extract for the prevention and treatment of hyperlipidemia and fatty liver
WO2016206363A1 (en) Use of jilin ginseng oligopeptide in preparation of anti-oxidant food product or health care food product
KR101241455B1 (en) Bean curd having hypotensive effect
KR101845704B1 (en) Composition comprising kynurenic acid for relieving hangover
JP2007051103A (en) Antioxidant composition
JP2009185004A (en) Agent for easing metabolic syndrome
JPWO2008123417A1 (en) Anti-fatigue
KR20160056655A (en) Composition for inhibiting obesity comprising complex salt of baicalin and zinc
JP2007099671A (en) Antioxidant composition
JP2019180412A (en) Oral composition
CN1674926A (en) Remedy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140324

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140324

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150318

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150930